Brokerages Set Scholar Rock Holding Corporation (NASDAQ:SRRK) Target Price at $51.14

Scholar Rock Holding Corporation (NASDAQ:SRRK) has been given a consensus rating of “Buy” by the seventeen ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and four have assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $51.1429.

A number of equities analysts have issued reports on SRRK shares. Citigroup started coverage on shares of Scholar Rock in a research report on Friday, January 9th. They issued a “buy” rating and a $55.00 price objective on the stock. UBS Group initiated coverage on Scholar Rock in a report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price target on the stock. JPMorgan Chase & Co. upped their price target on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Friday, November 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $44.27 on Thursday. The company has a market capitalization of $4.52 billion, a P/E ratio of -14.05 and a beta of 0.67. Scholar Rock has a fifty-two week low of $22.71 and a fifty-two week high of $49.82. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The stock has a 50 day moving average price of $45.36 and a two-hundred day moving average price of $38.86.

Insiders Place Their Bets

In related news, insider Mo Qatanani sold 136,462 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $45.21, for a total transaction of $6,169,447.02. Following the transaction, the insider owned 108,964 shares in the company, valued at $4,926,262.44. The trade was a 55.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David Hallal sold 57,450 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $2,453,115.00. Following the completion of the sale, the chief executive officer owned 1,541,645 shares of the company’s stock, valued at $65,828,241.50. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 344,932 shares of company stock worth $15,371,225. Company insiders own 13.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Moody Aldrich Partners LLC raised its holdings in Scholar Rock by 53.5% in the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock worth $3,789,000 after purchasing an additional 35,481 shares during the period. Norges Bank bought a new stake in Scholar Rock during the second quarter valued at about $41,628,000. Voya Investment Management LLC increased its position in Scholar Rock by 18.1% in the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock worth $16,503,000 after buying an additional 67,839 shares in the last quarter. Ensign Peak Advisors Inc raised its stake in shares of Scholar Rock by 78.8% in the second quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock worth $21,275,000 after buying an additional 264,693 shares during the period. Finally, Nan Fung Trinity HK Ltd. purchased a new position in shares of Scholar Rock during the 3rd quarter valued at about $1,402,000. Institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).